Tim Garnett, MD

At Eli Lilly he led the successful development of therapeutics in women’s health care, endocrinology, and neuroscience resulting in multiple product launches globally. Dr. Garnett has extensive experience leading clinical development and in portfolio management, medical, regulatory, and safety functions, and he has a strategic understanding of the landscape for metabolic therapeutics. He is currently Board Chair of Ophirex, a public benefit corporation focused on developing an affordable, accessible, oral antivenom treatment and is a Board member of MapLight Therapeutics, Inc., a clinical stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating brain disorders.

In addition, Dr. Garnett is also a member of the Advisory Panel of Cambridge Innovation Capital and an equity partner at Recode Health Ventures LLC. He holds a Bachelor of Medicine and a Bachelor of Surgery (MBBS) from St. George’s, University of London, and is a Fellow of both the Faculty of Pharmaceutical Medicine (FFPM), and the Royal College of Obstetricians and Gynaecologists (FRCOG).